Table 2.
Parameter | Objective | Halcyon (H) | Helical Tomotherapy (HT) | Difference (H-HT) | p |
---|---|---|---|---|---|
Bowel | |||||
Mean [Gy] | Minimise | 21.2 ± 3.1 | 21.1 ± 2.8 | 0.1 ± 0.9 | 0.82 |
D1% [Gy] | ≤57.5 | 48.8 ± 1.7 | 47.4 ± 1.3 | 1.4 ± 0.7 | < 0.001 |
V40Gy [cm3] | ≤250 a | 226.3 ± 35.9 | 258.9 ± 60.5 | −32.6 ± 34.3 | 0.01 |
V30Gy [cm3] | ≤500 a | 413.4 ± 58.9 | 472.7 ± 90.0 | −59.4 ± 53.5 | 0.01 |
V15Gy [cm3] | ≤700 b | 1557.2 ± 359.9 | 1279.7 ± 296.5 | 277.4 ± 188.6 | 0.01 |
Sigmoid | |||||
D1% [Gy] | ≤57.5 | 50.5 ± 3.7 | 49.4 ± 3.8 | 1.1 ± 2.1 | 0.11 |
Bladder | |||||
D1% [Gy] | ≤57.5 | 48.8 ± 2.2 | 47.0 ± 1.1 | 1.8 ± 1.8 | 0.01 |
V40Gy [%] | ≤75 a | 60.0 ± 10.8 | 63.6 ± 16.6 | −3.6 ± 7.5 | 0.16 |
V30Gy [%] | ≤85 a | 76.9 ± 7.1 | 77.0 ± 12.5 | −0.1 ± 9.2 | 0.96 |
Rectum | |||||
D1% [Gy] | ≤57.5 | 48.1 ± 1.3 | 46.9 ± 0.7 | 1.2 ± 1.8 | 0.05 |
V40Gy [%] | ≤85 a | 66.6 ± 20.5 | 72.8 ± 21.7 | −6.2 ± 11.2 | 0.11 |
V30Gy [%] | ≤95 a | 81.9 ± 12.7 | 89.7 ± 14.7 | −7.8 ± 12.2 | 0.07 |
Spinal Cord | |||||
D1% [Gy] | ≤48.0 | 25.1 ± 17.9 | 25.6 ± 16.5 | −2.4 ± 4.4 | 0.12 |
Left Fem. Head | |||||
D1% [Gy] | ≤50.0 | 38.1 ± 3.6 | 39.4 ± 1.6 | −1.3 ± 3.2 | 0.24 |
Mean [Gy] | b | 16.4 ± 2.7 | 13.8 ± 2.5 | 2.6 ± 3.1 | 0.001 |
Right Fem. Head | |||||
D1% [Gy] | ≤50.0 | 36.3 ± 4.6 | 41.7 ± 2.9 | −5.4 ± 2.5 | < 0.001 |
Mean [Gy] | b | 16.1 ± 2.3 | 12.6 ± 1.3 | 3.5 ± 1.9 | < 0.001 |
Left Kidney | |||||
Mean [Gy] | ≤15 | 6.9 ± 5.0 | 7.5 ± 5.1 | −0.6 ± 1.5 | 0.22 |
Right Kidney | |||||
Mean [Gy] | ≤ | 6.6 ± 4.8 | 7.1 ± 4.2 | − 0.5 ± 2.1 | 0.52 |
Body | |||||
D1% [Gy] | ≤58.9 | 53.2 ± 1.4 | 49.9 ± 3.7 | 3.3 ± 4.1 | < 0.001 |
CI36Gy | < 1.6 b | 1.6 ± 0.2 | 2.0 ± 0.1 | −0.4 ± 0.2 | < 0.001 |
CI43Gy | < 1.1 b | 1.1 ± 0.1 | 1.3 ± 0.1 | −0.2 ± 0.1 | < 0.001 |
CIPaddick | b | 0.87 ± 0.04 | 0.90 ± 0.07 | −0.03 ± 0.08 | 0.01 |
CIPaddick_SIB | b | 0.71 ± 0.08 | 0.78 ± 0.15 | −0.07 ± 0.10 | 0.05 |
Vx%: volume receiving at least x% of the dose. Dx%: dose received by at least x% of the volume
a: soft constraints, expected to be fulfilled in 70–80% of the patients according to EMBRACE II guidelines
b: not included as optimisation constraint